Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials

Autor: Vergote, I., Elser, G., Votan, B., Farrelly, L., Roover, J. De, Bryce, J., Bois, A. du, Penninckx, B., Campo, J. Del, Pujade-Lauraine, E., Bamias, A., Calvert, P., Colombo, N., Pignata, S., Ledermann, J.A., Sehouli, J., Kristensen, G., Siddiqui, N., Tulunay, G., Pfisterer, J., Marth, C., Mirza, M., Ottevanger, P.B., Casado, A.

Publikováno v: International Journal of Gynecological Cancer, 23, 1339-43
International Journal of Gynecological Cancer, 23, 7, pp. 1339-43

The European Network for Gynaecological Oncological Trial groups (ENGOT) is a research network of the European Society of Gynaecological Oncology and was founded in Berlin in October 2007. Earlier, we reported on the ENGOT minimal requirements for tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::503cd3f91f90d4ccb32c6ee08cd369ee
https://hdl.handle.net/2066/186688

Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.

Autor: Boeckx N, Laer CV, Roover JD, Wilmsen B, Bruyninckx K, Pauwels S

Publikováno v: Acta clinica Belgica [Acta Clin Belg] 2015 Aug; Vol. 70 (4), pp. 237-43. Date of Electronic Publication: 2015 Jul 13.